Rao Fu, Ruoyao Qi, Hualong Xiong, Xing Lei, Yao Jiang, Jinhang He, Feng Chen, Liang Zhang, Dekui Qiu, Yiyi Chen, Meifeng Nie, Xueran Guo, Yuhe Zhu, Jinlei Zhang, Mingxi Yue, Jiali Cao, Guosong Wang, Yuqiong Que, Mujing Fang, Yingbin Wang, Yixin Chen, Tong Cheng, Shengxiang Ge, Jun Zhang, Quan Yuan, Tianying Zhang, Ningshao Xia
Antitumor therapies based on adoptively transferred T cells or oncolytic viruses have made significant progress in recent years, but the limited efficiency of their infiltration into solid tumors makes it difficult to achieve desired antitumor effects when used alone. In this study, an oncolytic virus (rVSV-LCMVG) that is not prone to induce virus-neutralizing antibodies was designed and combined with adoptively transferred T cells. By transforming the immunosuppressive tumor microenvironment into an immunosensitive one, in B16 tumor-bearing mice, combination therapy showed superior antitumor effects than monotherapy...
May 3, 2024: Signal Transduction and Targeted Therapy